Interactions between acute lymphoblastic leukemia and bone marrow stromal cells influence response to therapy

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Pediatric B precursor acute lymphoblastic leukemia (pre-B ALL) cure rates are improving, but relapses remain a challenge.
• Understanding the genetic basis of drug resistance is crucial for improving pre-B ALL treatment outcomes.

Purpose of the Study:

• To identify genes and pathways involved in drug resistance in pre-B ALL.
• To investigate the role of the bone marrow microenvironment in mediating drug resistance.

Main Methods:

• Oligonucleotide microarray analysis of 184 pre-B ALL specimens compared to normal CD34(+) cells.
• Identification of differentially expressed genes and affected canonical pathways.
• Experimental testing of bone marrow stromal cell protection against ALL therapies.

Main Results:

• Identified 20 signature genes, including CTGF, BMP-2, CXCR4, and IL7R, involved in bone marrow interactions.
• Observed distinct gene expression patterns in cytogenetically defined pre-B ALL subgroups.
• Demonstrated that bone marrow stromal cells confer significant protection against vincristine and cytosine arabinoside.

Conclusions:

• Gene deregulation and bone marrow microenvironment interactions contribute to pre-B ALL drug resistance.
• Targeting cellular interactions within the bone marrow microenvironment could sensitize leukemic cells to therapy.
• Identified novel therapeutic targets for improving ALL treatment outcomes.